[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100589020":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":18,"centralContacts":19,"locations":25,"responsibleParty":43,"collaborators":45,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":18,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":18,"studyType":62,"phases":63,"briefSummary":66,"conditions":67,"keywords":18,"overallStatus":28,"whyStopped":18,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Grit Biotechnology","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"GT719 Injection treatment group","EXPERIMENTAL","GT719 Injection",[13],"Biological: GT719 Injection",[15],{"type":16,"name":11,"description":11,"armGroupLabels":17,"otherNames":18},"BIOLOGICAL",[9],null,[20],{"name":21,"role":22,"phone":23,"phoneExt":18,"email":24},"Dehui Zou","CONTACT","+8613602100955","zoudehui@ihcams.ac.cn",[26],{"facility":27,"status":28,"city":29,"state":30,"zip":18,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences","RECRUITING","Tianjin","Tianjin Municipality","China","CN",{"type":34,"coordinates":35},"Point",[36,37],117.17667,39.14222,{"lat":37,"lon":36},[40,41],{"name":21,"role":22,"phone":23,"phoneExt":18,"email":24},{"name":21,"role":42,"phone":18,"phoneExt":18,"email":18},"PRINCIPAL_INVESTIGATOR",{"type":44,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR",[46],{"name":47,"class":48},"Institute of Hematology & Blood Diseases Hospital, China","OTHER","100589020","phase-1-gt719-injection-for-the-treatment-of-recurrentrefractory-cd19-positive-adult-b-cell-malignancies-100589020",false,"NCT06948981","GT719 Injection for the Treatment of Recurrent\u002FRefractory CD19 Positive Adult B-cell Malignancies","A Single-arm, Open-label, Phase I\u002FII Clinical Study of GT719 Injection for Recurrent\u002FRefractory CD19 Positive Adult B-cell Malignancies","Inclusion Criteria:\n\n1. Voluntarily enrolled in the study, signed an informed consent form, and willing and able to comply with the study protocol.\n\n   \\-\n2. Eastern Collaborative Oncology Group (ECOG) physical fitness status score of 0 or 1.\n\n   \\-\n3. CD19 positivity confirmed by flow cytometry and\u002For histopathology.\n\nExclusion Criteria:\n\n1. Primary immunodeficiency.\n\n   \\-\n2. History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months prior to enrollment, requiring systemic anticoagulant therapy.\n\n   \\-\n3. Any medical condition that may interfere with the evaluation of the safety or effectiveness of research and treatment;","ALL","18 Years","75 Years",{"count":60,"type":61},46,"ESTIMATED","INTERVENTIONAL",[64,65],"PHASE1","PHASE2","This study is a prospective single-arm open-labled phase I\u002FII clinical trial, including dose escalation and expansion phase, aims to evaluate the safety, efficacy, and cellular pharmacokinetics of GT719 Injection in relapsed\u002Frefractory CD19 positive adult B-cell non Hodgkin lymphoma (B-NHL) and B-acute lymphoblastic leukemia (B-ALL) patients. A total of 46 subjects (anticipated) will be enrolled in this study.",[68],"Hematological Malignancy (Leukemia- Lymphoma)","2025-09-10",{"date":71,"type":72},"2025-09-16","ACTUAL",{"date":74,"type":72},"2025-04-18",{"date":76,"type":61},"2028-04-17",{"name":5,"class":6},1]